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Oxidative stress causes endothelial dysfunction and is implicated in the pathogenesis of
cardiovascular diseases. Our studies suggested that reactive oxygen species (ROS) play a
crucial role in hereditary hemorrhagic telangiectasia (HHT) disease, a vascular dysplasia
affecting 1 in 5,000–8,000 people. Mutations in endoglin (ENG) and activin receptor-
like kinase 1 (ACVRL1) genes are responsible for HHT1 and HHT2 and are associated
with arteriovenous malformations. ENG and ACVRL1 interact with endothelial nitric oxide
synthase (eNOS) and regulate its activation. Mice heterozygous for these genes (Eng+/−
and Acvrl1+/−) show reduced ENG or ACVRL1 protein levels in endothelial cells causing
eNOS uncoupling, generation of ROS rather than nitric oxide (NO•), leading to impaired
NO• mediated vasodilation. ROS production is increased in several organs of Eng+/− and
Acvrl1+/− mice, including lungs, liver, and colon, affected in HHT. The major source of
increased oxidative stress in these tissues is eNOS-derived ROS and not mitochondrial
or NADPH oxidase-dependent ROS. Eng+/− and Acvrl1+/− mice also develop with age
signs of pulmonary arterial hypertension attributable to eNOS-derived ROS, which was
preventable by antioxidant treatment. To date, only one pilot study has been carried out
in HHT patients, and it showed beneficial effects of antioxidant therapy on epistaxis. We
suggest that more clinical studies are warranted to investigate whether antioxidants would
prevent, delay or attenuate manifestations of disease in individuals with HHT, based on our
experimental data in mouse models.
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INCREASED ROS PRODUCTION AND ENDOTHELIAL
DYSFUNCTION IN CARDIOVASCULAR DISEASES
Reactive oxygen species (ROS) are important regulators of
many processes including intracellular signaling, response to
growth factor stimulation and generation of the inflammatory
response (Finkel, 2011). Dysregulated ROS signaling, leading
to increased free radical production and/or down regulation
of ROS scavengers and antioxidants, may cause or accelerate
many pathological conditions, including cardiovascular, neurode-
generative, and malignant diseases. Oxidative stress is associ-
ated with endothelial dysfunction in cardiovascular disorders
such as systemic and pulmonary hypertension, atherosclerosis,
and diabetes (Münzel et al., 2010). Understanding the mecha-
nisms of excessive ROS production and their role in endothe-
lial damage may provide opportunities for pharmacological
intervention.
The major enzymatic sources of ROS in endothelial cells
are mitochondrial respiratory enzymes, NADPH oxidases and
uncoupled endothelial nitric oxide synthase (eNOS). It is impor-
tant to mention that increased ROS production together with
decreased nitric oxide (NO•) bioavailability can further com-
plicate and worsen endothelial injury (Montezano and Touyz,
2012a). It is also recognized that crosstalk between various sources
of ROS exists and may represent a feed-forward vicious cycle of
ROS production (Dikalov, 2011).
Mitochondria produce ROS during ATP generation, when
electrons transferred through the respiratory chain “leak” and
create superoxide (•O2−; Widlansky and Gutterman, 2011),
which can then be scavenged by the superoxide dismutase 2
(SOD2) present in the mitochondrial matrix. The release of ROS
depends on activation of mitochondrial ATP-sensitive potassium
channels (mitoKATP) and opening of the permeability transi-
tion pores (PTP). Interestingly, NO• affects mitoKATP activation
(Figure 1) and low levels induce mitochondrial ROS release
causing additional cellular oxidative stress (Chang et al., 2010).
Excessive production of mitochondrial ROS can be targeted by
specific inhibitors of the electron respiratory chain, such as
antimycin A (Kudin et al., 2008) or by increased ROS scavenging.
Recent animal studies have demonstrated that overexpression of
SOD2 reduces fibrosis and pro-apoptotic signaling in the aging
mouse heart (Kwak et al., 2014), while MitoTEMPOL, an SOD
mimetic drug that concentrates in mitochondria, significantly
reduced H2O2- and lipid peroxide-induced endothelial oxidative
stress (Dhanasekaran et al., 2005).
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FIGURE 1 | NO production in normal endothelium. In wild type mice
(Eng+/+and Alk1+/+) eNOS is closely associated with caveolae/lipid rafts in
endothelial cells. Endoglin and ALK-1 co-localize with eNOS serving as
scaffolding molecules for eNOS/Hsp90 association and eNOS activation,
leading to NO• production. Normal cellular NO• levels through
mitochondrial ATP-sensitive potassium channels (mitoKATP) and closed
permeability transition pores (PTP) prevent mitochondrial ROS “leak” into
the cytoplasm. Small amount of ROS, produced by NADPH oxidases, are
involved in cell signaling (adapted from Jerkic et al., 2012).
NADPH oxidases are a family of enzyme complexes, which
catalyze the transfer of electrons from NADPH to molecular O2
via their “Nox” catalytic subunit, generating •O2− and H2O2
(Dikalov, 2011; Figure 1). The major Nox isoforms present
in endothelial cells are Nox4 and Nox5. ROS generated from
NADPH oxidases also affect redox-sensitive mitoKATP activation,
since inhibition of NADPH oxidases by apocynin completely
prevented mitochondrial dysfunction induced by Angiotensin II
(AngII; Doughan et al., 2008). NADPH oxidases also appear to be
a major source of ROS in vessels of spontaneously hypertensive
rats, as demonstrated by blocking with the novel and more
specific NADPH oxidase inhibitor VAS3947 (Wind et al., 2010).
Studies on arteries from patients with coronary artery disease
and in animals with experimentally induced systemic hyper-
tension, diabetes, or atherosclerosis, suggest that Nox1, Nox2,
and Nox5 promote endothelial dysfunction (Drummond and
Sobey, 2014, whereas contribution of Nox4 has been proposed
in lung vessel remodeling caused by pulmonary hypertension
(Barman et al., 2014). The anti-hypertensive effect of angiotensin-
converting enzyme (ACE) inhibitors and AT1 receptor antago-
nists has been attributed in part to their ability to inhibit AngII-
induced NADPH oxidase activation and expression (Schramm
et al., 2012).
Endothelial nitric oxide synthase is closely associated with
caveolae/lipid rafts, and critically involved in NO• production.
Multiple factors influence eNOS activation, mediated through
Akt-dependent phosphorylation at Ser1177, and inhibited by
phosphorylation at Thr459 (Dimmeler et al., 1999). Basal eNOS
activity correlates with the amount of tetrahydrobiopterin (BH4)
bound to the enzyme. eNOS uncoupling occurs when there is
a discrepancy between eNOS levels and NO• production, with
a switch in the eNOS enzymatic activity to generate superox-
ide rather than NO• (Montezano and Touyz, 2012a). eNOS
uncoupling is implicated in endothelial dysfunction and has been
demonstrated in experimental models and patients with hyper-
tension (essential, renovascular, malignant, and salt-sensitive),
diabetes, atherosclerosis, and cardiac failure (Moens and Kass,
2007). Very limited NO• bioavailability combined with overly
abundant ROS is one of the key factors causing endothelial
damage and vascular dysfunction in these disorders. Moreover,
classical antihypertensive agents (β-adrenergic blockers, ACE
inhibitors, AT1 receptor blockers and Ca2+-channel blockers)
exert some of their beneficial effects by stimulating NO• pro-
duction and decreasing vascular ROS bioavailability (Weseler and
Bast, 2010). Resveratrol, BH4, sepiapterin, and folic acid have also
been shown to recouple eNOS and improve endothelial function
in animal studies (Li and Forstermann, 2014).
HHT AND OXIDATIVE STRESS
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal
dominant vascular dysplasia with age-related penetrance, affect-
ing 1 in 5,000–8,000 people worldwide. The external visible signs
of HHT are recurrent epistaxis (nosebleeds) and small cuta-
neous telangiectatic lesions. Imaging studies reveal the presence
of arteriovenous malformations (AVMs)—defined as abnormal
direct connections between arteries and veins—in lungs, liver, and
brain. AVMs are life-threatening because of their potentially lethal
complications such as stroke, hemorrhage, and brain abscess.
HHT is a genetically heterogeneous disorder, HHT type 1 (HHT1)
is caused by mutations in the ENG (endoglin) gene located on
chromosome 9, region 9q33-q34, whereas HHT type 2 (HHT2) is
caused by mutations in the ACVRL1 (activin receptor-like kinase
1 or ALK-1) gene located on chromosome 12, region 12q11-q14.
About 15–20% of HHT families remain unresolved after mutation
analysis of these two genes (McDonald et al., 2011), and two more
genetic loci have been implicated, HHT3 on chromosome 5 (Cole
et al., 2005; Govani and Shovlin, 2010) and HHT4 on chromo-
some 7 (Bayrak-Toydemir et al., 2006), though the causative genes
remain unidentified. A subset of patients (2–3%) with a combined
syndrome of juvenile polyposis and HHT (defined as JPHT)
harbor mutations in the MADH4 (SMAD4) gene (Gallione et al.,
2004). More recently, mutations in the BMP9 (GDF2) gene have
been associated with an HHT-like syndrome. BMP9 mutations
cause a vascular-anomaly syndrome with phenotypic overlap with
HHT (Wooderchak-Donahue et al., 2013).
The underlying mechanism of HHT1 and HHT2 is haploin-
sufficiency indicating that reduced amounts of ENG and ACVRL1
lead to endothelial dysfunction and predispose to the clinical signs
of disease. The observations that BMP9 is the highest affinity lig-
and for ACVRL1 and ENG and that Smad4 is a downstream medi-
ator support the hypothesis that BMP9/ACVRL1/ENG/Smad4
mediated pathways are affected in HHT.
Despite the fact that vascular stress and multi-organ vascular
dysplasia are hallmarks of HHT (Abdalla and Letarte, 2006), only
few studies have been investigating the role of oxidative stress in
the pathogenesis of this disease. We will summarize our results
in mouse models of HHT, which implicate oxidative stress as an
underlying mechanism of endothelial dysfunction in this disease.
MOUSE MODELS OF HHT, ENDOTHELIAL DYSFUNCTION, AND eNOS
UNCOUPLING
Endoglin and Acvrl1 heterozygous (Eng+/− and Acvrl1+/−) mice
have been used as models for HHT1 and HHT2 respectively,
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FIGURE 2 | Model of oxidative stress in mutant mice leading to
vascular endothelial damage. In Eng+/− and Alk1+/− mice, altered eNOS
activation renders the enzyme refractory to regulation by TGF-β/BMP
signaling and represents a critical event leading to excessive oxidative
stress. Uncoupled eNOS produces low amounts of NO• and high levels of
oxygen radicals (•O2−). The NOS inhibitor L-NAME inhibits ROS production
in tissues of Eng+/− and Alk1+/− mice. Superoxide dismutase (SOD) and
the SOD mimetic compound Tempol, converts •O2− into less harmful
hydrogen peroxide (H2O2). A large portion of ROS is produced by
mitochondria (Antimycin-inhibitable) and NADPH oxidases
(Apocynin-inhibitable), however, that percentage does not differ between
mutant and control mice. The low NO• cellular level associated with HHT
may also inhibit mitochondrial ATP-sensitive potassium channel (mitoKATP)
opening, trigger permeability transition pores (PTP) opening and further
increase the oxidative stress caused by mitochondrial ROS release (adapted
from Jerkic et al., 2012).
allowing us to dissect the underlying mechanisms of disease
(Bourdeau et al., 1999; Srinivasan et al., 2003). Early generations
of Eng+/− mice developed multiple signs of HHT in many organs,
likely due to modifier genes in the 129/Ola background (Bourdeau
et al., 2001). Subsequent backcrossing to the C57BL/6J back-
ground gave rise to mice with no apparent symptoms of HHT,
but allowed us to study the underlying endothelial dysfunction.
Physiological studies revealed that ENG is involved in the control
of vascular tone regulating NO-dependent vasodilatation (Jerkic
et al., 2004). Resistance arteries from Eng+/− C57BL/6J mice
showed enhanced endothelial-dependent dilatation and impaired
myogenic response (Toporsian et al., 2005). Furthermore, ENG
could be found in caveolae, where it associates with eNOS and
likely stabilizes it. eNOS is closely associated with caveolae/lipid
rafts in endothelial cells (Pritchard et al., 2001), where ENG and
ALK-1 colocalize with eNOS serving as scaffolding molecules for
eNOS/Hsp90 association, eNOS activation, and NO• production
(Toporsian et al., 2005). ENG-deficient endothelial cells, follow-
ing Ca2+ activation, showed reduced eNOS/Hsp90 interaction,
produced less NO• and generated more eNOS-derived superoxide
(•O2−), indicating that ENG is an important regulator in the
coupling of eNOS activity (Toporsian et al., 2005). Treatment of
Eng+/− resistance arteries with the anti-oxidant Tiron, reversed
the vascular abnormalities (Toporsian et al., 2005), confirming
that ROS are implicated in the pathobiology of HHT. Acvrl1 was
also shown to associate with the eNOS activation complex leading
to NO• production (Toporsian et al., 2010). Consequently, in
endothelial cells deficient in ENG or Acvrl1, eNOS becomes
uncoupled and produces more superoxide than NO•, leading to
endothelial damage (Figure 2).
eNOS-DERIVED ROS ARE ONLY PRESENT IN ADULT LUNGS OF Eng
AND Acvrl1 HETEROZYGOUS MICE
We addressed the age-dependency of ROS production in lungs of
Eng and Acvrl1 heterozygous mice. ROS generation was higher
in adult than newborn mice, in both mutant and control mice,
and so were the levels of NADPH oxidase and ROS scavenging
SOD 1, 2, and 3 isoforms (Belik et al., 2009; Jerkic et al., 2011),
indicating maturational changes of these enzymes. There was no
difference in ROS levels between newborn mutant mice and their
littermate controls, while adult mutant mice showed increased
levels of pulmonary oxidative stress than control mice. Protein
levels and NADPH activity were normal in adult Eng+/− and
Acvrl1+/− lungs as well as the levels of scavenging enzymes and
could not account for the increased oxidative stress. However,
eNOS-dependent ROS production was increased in adult mutant
mice while NO• production was reduced. Thus Eng and Acvrl1
haploinsufficiency results in pulmonary vascular eNOS uncou-
pling in the adult, but not newborn mice (Belik et al., 2009; Jerkic
et al., 2011).
Pulmonary arteries from adult Eng+/− and Acvrl1+/− mice
were more dilated compared to the control animals. More-
over, several signs of pulmonary arterial hypertension (PAH),
including elevated right ventricular systolic pressure leading to
hypertrophy, reduced vascular density, and increased thickness
and outward remodeling of pulmonary arterioles, were observed
in adult but not newborn Eng+/− and Acvrl1+/− mice relative
to wild-type littermate controls. Our observations support the
fact that mutations in several genes of the TGF-β superfamily,
including BMPR2, ACVRL1, and ENG, predispose to PAH (Girerd
et al., 2010). Interestingly, treatment of 3-week-old Eng+/− and
Acvrl1+/− mice with the SOD mimetic and anti-oxidant Tempol
for 6 weeks prevents the onset of PAH symptoms in these mice,
confirming a role for ROS in the pathobiology of the disease.
These findings also suggest that an abnormal regulation of ROS
might play a role in the formation of pulmonary AVMs in HHT.
MULTIPLE ORGANS OF Eng AND Acvrl1 HETEROZYGOUS MICE SHOW
INCREASED ROS
Results of a more recent study (Jerkic et al., 2012) suggest that
oxidative stress is indeed a generalized manifestation in organs
of Eng and Acvrl1 heterozygous mice. We have found increased
ROS production in lungs, liver, and colon of the heterozygous
mice, organs most frequently affected in HHT patients. Our
results also indicate that increased oxidative stress contributes
to endothelial dysfunction in mutant mice. Mitochondrial ROS
production was highest in liver while NADPH oxidase was a
major source of ROS in the other tissues. However, there was
no difference in mitochondrial- or NADPH oxidase-dependent
ROS production between mutant and control mice. In tissues
of mutant mice ROS overproduction was attributed to NOS, as
it was L-NAME inhibitable. As neuronal NOS was not observed
and inducible NOS was barely detectable in mouse tissues (Jerkic
et al., 2004, 2011), we conclude that the observed increase in
ROS production in HHT mice is eNOS-derived and therefore
endothelial-dependent.
A recent paper from Ghanian et al. (2014) has explored the
mitochondrial redox state in kidneys and eyes of Eng heterozy-
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gous mice using optical imaging. They found that mitochondrial
oxidative stress was decreased in these organs of Eng+/− mice. We
cannot comment on these findings, as we have not explored eye or
kidney ROS production and have focused on organs most affected
in HHT.
Overall, we have documented in several papers an increased
oxidative stress in endothelial cells and tissues of Eng and Acvrl1
heterozygous mice and identified uncoupled eNOS as a source
of ROS overproduction (Figure 2). However, increased ROS
concentration and decreased NO• bioavailability have further
effects on ROS production and/or release from other sources, as
discussed previously. Low NO• cellular levels inhibit mitoKATP
and trigger the opening of PTP. This process causes ROS release
from mitochondria (Figure 2), worsening oxidative stress and
leading eventually to the AVMs characteristic of HHT.
The role of oxidative stress has also been recently suggested
in the pathogenesis of endothelial dysfunction in pre-eclampsia,
disease associated with increased production from the placenta
of a soluble form of ENG (sEng; Venkatesha et al., 2006). Tski-
tishvili et al. (2010) have demonstrated that cultured placental and
amniotic tissues release sEng under oxidative stress, in connection
with endothelial dysfunction, systemic inflammation, and pre-
eclampsia.
ANTIOXIDANTS IN CARDIOVASCULAR DISEASES
The excessive generation of ROS and/or reduced antioxidant
capacity lead to endothelial dysfunction. One can therefore pro-
pose that correction of the abnormally elevated ROS bioavailabil-
ity might retard, or prevent, endothelial cell injury. Antioxidants
could represent a simple way to restore the redox status in the
vascular milieu (Münzel et al., 2010). However, experimental
and clinical studies that tested preventive or therapeutic use of
antioxidants have shown that their use is much more complex and
context-dependent.
Tuomilehto et al. (1987) have observed lower cardiovascular
mortality in Mediterranean populations compared to those of
Northern European countries and attributed the differences to
the higher content of antioxidants in the Mediterranean diet. The
Zutphen Elderly study confirmed a negative correlation between
antioxidant vitamin intake and coronary heart disease and mor-
tality in 805 elderly men without prior history of cardiovascular
disease (Hertog et al., 1993). In line with these studies, a meta-
analysis of cohort studies including almost 400,000 patients (Ye
and Song, 2008) reported that high intake of antioxidant vitamins
(C and E) was associated with a lower rate of coronary heart
disease. However, none of the above-mentioned clinical trials
directly demonstrated that the dose and type of antioxidants
used effectively suppressed oxidative stress. In that context, results
from the few studies that assessed antioxidant intake based on
specific blood assays were more ambiguous. The ATBC study that
followed 29,000 male smokers for 19 years showed that higher
levels of vitamin E in the serum (but still within the physio-
logical range) were associated with lower mortality for prostate
cancer and cardiovascular disease (The Alpha Tocopherol, Beta
Carotene Cancer Prevention Study Group, 1994). However, in the
same study the group that received beta-carotene showed greater
mortality from lung cancer. The NHANES-II study, with 8,000
enrolled subjects, showed that men but not women in the lowest
quartile of serum vitamin C had an increased mortality for cancer
and cardiovascular disease (Loria et al., 2000). Reasons for these
equivocal and sometimes disappointing results relate to the type
and dose of antioxidants used, patient cohorts, trial design, and
choice of outcome measures. It is also possible that dose and
duration of the antioxidant therapy were insufficient. Please refer
to Hasnain and Mooradian (2004) and Stephens et al. (2009) for
a detailed discussion of these findings.
Another important requirement for the clinical use of antioxi-
dants is to develop and validate markers of oxidative stress, triage
the patients with oxidative excess and measure efficacy of the
treatment. It is also necessary to know the organs most affected
and the major source of ROS in a particular patient, in order
to choose the right antioxidant and the most efficient way for
its delivery. In controlled preclinical studies and clinical trials of
statins and antihypertensive drugs mentioned above, oxidative
stress and NO• production were assessed. These drugs were
shown to improve vascular function and reduce the incidence
of cardiovascular events in patients with cardiovascular disease,
at least partly by increasing NO• and reducing ROS production
(Chen et al., 2008; Münzel et al., 2010; Weseler and Bast, 2010;
Montezano and Touyz, 2012b).
ANTIOXIDANTS IN HHT
We have shown using mouse models that excessive ROS gener-
ation may play a pivotal role in the pathobiology of endothelial
dysfunction in HHT (Jerkic et al., 2012). Our results suggest that
HHT patients may indeed benefit from diets rich in antioxidants,
which could prevent or delay the rise in ROS in their blood vessels,
due to eNOS uncoupling. Our studies showed that supplementing
drinking water with the antioxidant Tempol for 6 weeks prevented
rarefaction of the lung vasculature and the onset of PAH in
Eng and Acvrl1 heterozygous mice (Toporsian et al., 2010; Jerkic
et al., 2011). In HHT patients, the only trial carried out to date
was a pilot study in which the antioxidant N-acetylcysteine was
given to the patients for 12 weeks (de Gussem et al., 2009). The
results of this study showed beneficial effects of this antioxidant
therapy with a significant decrease in the frequency and severity
of epistaxis in treated HHT patients, improving their quality of
life. No preventative dietary study has been carried out, although
some patients with HHT have mentioned reduced nosebleeds
upon maintenance on diets rich in anti-oxidants.
We propose that antioxidants are promising tools in HHT,
both as preventative and therapeutic options. Prevention of
endothelial dysfunction in HHT patients may include simple
strategies such as an antioxidant-rich diet, abstinence from smok-
ing, a healthier lifestyle, and regular physical activity and exercise.
It has been shown that exercise can prevent eNOS uncoupling,
reduce NADPH oxidase activity and decrease endothelial oxida-
tive stress and dysfunction in experimental models and patients
with coronary artery disease (Adams et al., 2005; Agarwal et al.,
2011). The therapeutic use of antioxidants is much more complex
and as mentioned above requires considerations of the appropri-
ate compound and proper dosage, the affected organ, individual
response to treatment, and monitoring of the therapy. The choice
of the right antioxidant is most critical. We have shown that
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Tempol in particular is an effective antioxidant and it could be
a good candidate for clinical trials in HHT patients. Tempol was
successfully used in more than 70 animal studies, in diseases
associated with oxidative stress, inflammation, and aging (Wilcox,
2010). Two clinical trials are presently ongoing, with the use of
Tempol as a topical agent to prevent radiation-induced alope-
cia and for dermatitis during radiation and chemotherapy for
anal cancer (http://www.paidclinicaltrials.org/dir/category/by-
medicine/tt/tempol). Our experimental findings suggest that the
use of antioxidants could prevent uncoupling of eNOS associated
with HHT. Whether it could cause eNOS recoupling in affected
organs of HHT patients remains to be tested.
In conclusion, oxidative stress plays a causative role in the
pathogenesis of endothelial dysplasia and vascular malformations
in HHT. The use of antioxidants in the prevention and treatment
of HHT should be of benefit to the patients. More experimental
and clinical studies are urgently needed to test the most effective
ways to use antioxidants to ameliorate the quality of life for
patients with HHT.
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